These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28179443)

  • 21. "Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease": a consensus document.
    Alcázar Navarrete B; Casanova C; Miravitlles M; de Lucas P; Riesco JA; Rodríguez González-Moro JM;
    Arch Bronconeumol; 2015 Apr; 51(4):193-8. PubMed ID: 25540900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current drug treatment, chronic and acute.
    Calverley P
    Clin Chest Med; 2014 Mar; 35(1):177-89. PubMed ID: 24507845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.
    Singh D; Roche N; Halpin D; Agusti A; Wedzicha JA; Martinez FJ
    Am J Respir Crit Care Med; 2016 Sep; 194(5):541-9. PubMed ID: 27585383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel combined candidate--new hopes for COPD maintenance therapy!?
    Mihălţan F; Ulmeanu R
    Pneumologia; 2015; 64(3):9-11. PubMed ID: 26740985
    [No Abstract]   [Full Text] [Related]  

  • 26. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trelegy Ellipta--a three-drug inhaler for COPD.
    Med Lett Drugs Ther; 2018 May; 60(1547):86-88. PubMed ID: 29913467
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response.
    Rho J; Ho N; Prasad V
    Chest; 2015 Jul; 148(1):e31-e32. PubMed ID: 26149564
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The reasons for triple therapy in stable COPD patients in Japanese clinical practice.
    Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.
    Ding B; Small M
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rebuttal from Drs Suissa and Rabe.
    Suissa S; Rabe KF
    Chest; 2014 May; 145(5):942-3. PubMed ID: 24798832
    [No Abstract]   [Full Text] [Related]  

  • 35. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
    Rabe KF; Bateman ED; O'Donnell D; Witte S; Bredenbröker D; Bethke TD
    Lancet; 2005 Aug 13-19; 366(9485):563-71. PubMed ID: 16099292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
    Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current anti-inflammatory therapy in patients with chronic obstructive pulmonary disease].
    Shmelev EI; Shmeleva NM
    Ter Arkh; 2012; 84(6):73-6. PubMed ID: 22997924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Point: were industry-sponsored roflumilast trials appropriate? Yes.
    Suissa S; Rabe KF
    Chest; 2014 May; 145(5):937-9. PubMed ID: 24798830
    [No Abstract]   [Full Text] [Related]  

  • 39. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of pharmacologic treatment based on airflow limitation and breathlessness on daily physical activity in patients with chronic obstructive pulmonary disease.
    Minakata Y; Morishita Y; Ichikawa T; Akamatsu K; Hirano T; Nakanishi M; Matsunaga K; Ichinose M
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1275-82. PubMed ID: 26170656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.